NeuroSense Therapeutics Reports Q1 2024 Results
Ticker: NRSNW · Form: 6-K · Filed: Jun 24, 2024 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, financial-results, 6-K
TL;DR
NeuroSense dropped Q1 2024 results & corporate update on 6/24.
AI Summary
NeuroSense Therapeutics Ltd. filed a Form 6-K on June 24, 2024, to report its corporate update and first quarter 2024 financial results. The filing includes a press release detailing these updates, furnished as Exhibit 99.1.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for NeuroSense Therapeutics, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a clinical-stage biotechnology company, NeuroSense Therapeutics faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the 6-K report
- June 24, 2024 (date) — Date of the press release and filing
- Exhibit 99.1 (document) — Press release furnished with the 6-K
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K filing is to report NeuroSense Therapeutics Ltd.'s corporate update and first quarter 2024 financial results, including a press release as Exhibit 99.1.
When was the press release regarding the corporate update and financial results issued?
The press release was issued on June 24, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
Does NeuroSense Therapeutics file annual reports under Form 20-F or Form 40-F?
NeuroSense Therapeutics indicates that it files annual reports under Form 20-F.
What is the SIC code for NeuroSense Therapeutics Ltd.?
The Standard Industrial Classification (SIC) code for NeuroSense Therapeutics Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 290 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2024-06-24 09:20:19
Filing Documents
- ea0208354-6k_neurosense.htm (6-K) — 12KB
- ea020835401ex99-1_neurosense.htm (EX-99.1) — 92KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-055014.txt ( ) — 108KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: June 24, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 3